FDA Changes Course, Advises Updated COVID-19 Vaccines Target KP.2 Strain

Decision runs counter to recommendations from agency’s advisers.

A healthcare worker prepares a COVID-19 vaccine in New York City in a file photograph. Michael M. Santiago/Getty Images

The U.S. Food and Drug Administration (FDA) on June 13 changed course and recommended COVID-19 manufacturers target the KP.2 virus strain in their next round of shots.

The regulatory agency had said earlier this month it was following advice from its advisers and directing manufacturers to target the JN.1 variant.